Related references
Note: Only part of the references are listed.Sensitivity of plasma BRAF(mutant) and NRAS(mutant) cell-free DNA assays to detect metastatic melanoma in patients with low RECIST scores and non-RECIST disease progression
Gregory A. Chang et al.
MOLECULAR ONCOLOGY (2016)
Mixed Effects Modeling Using Stochastic Differential Equations: Illustrated by Pharmacokinetic Data of Nicotinic Acid in Obese Zucker Rats
Jacob Leander et al.
AAPS JOURNAL (2015)
Integrated PK-PD and agent-based modeling in oncology
Zhihui Wang et al.
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS (2015)
Therapy-induced tumour secretomes promote resistance and tumour progression
Anna C. Obenauf et al.
NATURE (2015)
Adaptive stress signaling in targeted cancer therapy resistance
E. Pazarentzos et al.
ONCOGENE (2015)
Treatment Analysis in a Cancer Stem Cell Context Using a Tumor Growth Model Based on Cellular Automata
Angel Monteagudo et al.
PLOS ONE (2015)
Quantitative Cell-Free Circulating BRAF(V600E) Mutation Analysis by Use of Droplet Digital PCR in the Follow-up of Patients with Melanoma Being Treated with BRAF Inhibitors
Miguel F. Sanmamed et al.
CLINICAL CHEMISTRY (2015)
Computational Modeling of Tumor Response to Drug Release from Vasculature-Bound Nanoparticles
Louis T. Curtis et al.
PLOS ONE (2015)
Agent-Based Modeling in Systems Pharmacology
J. Cosgrove et al.
CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY (2015)
Current Status of Imaging and Emerging Techniques to Evaluate Liver Metastases From Colorectal Carcinoma
Dushyant V. Sahani et al.
ANNALS OF SURGERY (2014)
Drug Resistance via Feedback Activation of Stat3 in Oncogene-Addicted Cancer Cells
Ho-June Lee et al.
CANCER CELL (2014)
Bridging Population and Tissue Scale Tumor Dynamics: A New Paradigm for Understanding Differences in Tumor Growth and Metastatic Disease
Jill Gallaher et al.
CANCER RESEARCH (2014)
The paradigm of mutant p53-expressing cancer stem cells and drug resistance
Yoav Shetzer et al.
CARCINOGENESIS (2014)
Noninvasive Detection of Response and Resistance in EGFR-Mutant Lung Cancer Using Quantitative Next-Generation Genotyping of Cell-Free Plasma DNA
Geoffrey R. Oxnard et al.
CLINICAL CANCER RESEARCH (2014)
The risk of developing a second primary cancer in melanoma patients: A comprehensive review of the literature and meta-analysis
Saverio Caini et al.
JOURNAL OF DERMATOLOGICAL SCIENCE (2014)
Evolution of acquired resistance to anti-cancer therapy
Jasmine Foo et al.
JOURNAL OF THEORETICAL BIOLOGY (2014)
Acquired resistance to TKIs in solid tumours: learning from lung cancer
D. Ross Camidge et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2014)
Combined Vemurafenib and Cobimetinib in BRAF-Mutated Melanoma
James Larkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
Chetan Bettegowda et al.
SCIENCE TRANSLATIONAL MEDICINE (2014)
Epigenetic mechanisms of importance for drug treatment
Maxim Ivanov et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2014)
MAP Kinase Pathway Alterations in BRAF-Mutant Melanoma Patients with Acquired Resistance to Combined RAF/MEK Inhibition
Nikhil Wagle et al.
CANCER DISCOVERY (2014)
Circulating tumor DNA analysis as a real-time method for monitoring tumor burden in melanoma patients undergoing treatment with immune checkpoint blockade
Evan J. Lipson et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2014)
Poised epigenetic states and acquired drug resistance in cancer
Robert Brown et al.
NATURE REVIEWS CANCER (2014)
Mutation-based detection and monitoring of cell-free tumor DNA in peripheral blood of cancer patients
L. Benesova et al.
ANALYTICAL BIOCHEMISTRY (2013)
Modeling vascularized bone regeneration within a porous biodegradable CaP scaffold loaded with growth factors
Xiaoqiang Sun et al.
BIOMATERIALS (2013)
The Dynamics of Signaling as a Pharmacological Target
Marcelo Behar et al.
CELL (2013)
Resistance to BRAF Inhibition in BRAF-Mutant Colon Cancer Can Be Overcome with PI3K Inhibition or Demethylating Agents
Muling Mao et al.
CLINICAL CANCER RESEARCH (2013)
Tumour heterogeneity and cancer cell plasticity
Corbin E. Meacham et al.
NATURE (2013)
Analysis of Circulating Tumor DNA to Monitor Metastatic Breast Cancer
Sarah-Jane Dawson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Systems Modeling of Anti-apoptotic Pathways in Prostate Cancer: Psychological Stress Triggers a Synergism Pattern Switch in Drug Combination Therapy
Xiaoqiang Sun et al.
PLOS COMPUTATIONAL BIOLOGY (2013)
Cancer drug resistance: an evolving paradigm
Caitriona Holohan et al.
NATURE REVIEWS CANCER (2013)
Cytokine combination therapy prediction for bone remodeling in tissue engineering based on the intracellular signaling pathway
Xiaoqiang Sun et al.
BIOMATERIALS (2012)
Multi-scale agent-based brain cancer modeling and prediction of TKI treatment response: Incorporating EGFR signaling pathway and angiogenesis
Xiaoqiang Sun et al.
BMC BIOINFORMATICS (2012)
Computational Modeling of Pancreatic Cancer Reveals Kinetics of Metastasis Suggesting Optimum Treatment Strategies
Hiroshi Haeno et al.
CELL (2012)
Epigenetic mechanisms in tumorigenesis, tumor cell heterogeneity and drug resistance
Roel H. Wilting et al.
DRUG RESISTANCE UPDATES (2012)
The Akt Inhibitor MK2206 Synergizes, but Perifosine Antagonizes, the BRAFV600E Inhibitor PLX4032 and the MEK1/2 Inhibitor AZD6244 in the Inhibition of Thyroid Cancer Cells
Ruixin Liu et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2012)
Effects of Pharmacokinetic Processes and Varied Dosing Schedules on the Dynamics of Acquired Resistance to Erlotinib in EGFR-Mutant Lung Cancer
Jasmine Foo et al.
JOURNAL OF THORACIC ONCOLOGY (2012)
Combinations of BRAF, MEK, and PI3K/mTOR Inhibitors Overcome Acquired Resistance to the BRAF Inhibitor GSK2118436 Dabrafenib, Mediated by NRAS or MEK Mutations
James G. Greger et al.
MOLECULAR CANCER THERAPEUTICS (2012)
Genetic heterogeneity and cancer drug resistance
Nicholas C. Turner et al.
LANCET ONCOLOGY (2012)
Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion
Ravid Straussman et al.
NATURE (2012)
Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations
Keith T. Flaherty et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
In silico Experimentation of Glioma Microenvironment Development and Anti-tumor Therapy
Yu Wu et al.
PLOS COMPUTATIONAL BIOLOGY (2012)
Mathematical Modeling Predicts Synergistic Antitumor Effects of Combining a Macrophage-Based, Hypoxia-Targeted Gene Therapy with Chemotherapy
Markus R. Owen et al.
CANCER RESEARCH (2011)
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
Paul B. Chapman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
The evolution of tumor metastases during clonal expansion
Hiroshi Haeno et al.
JOURNAL OF THEORETICAL BIOLOGY (2010)
Prediction of Drug Response in Breast Cancer Using Integrative Experimental/Computational Modeling
Hermann B. Frieboes et al.
CANCER RESEARCH (2009)
Tumor-Immune Interaction, Surgical Treatment, and Cancer Recurrence in a Mathematical Model of Melanoma
Steffen Eikenberry et al.
PLOS COMPUTATIONAL BIOLOGY (2009)
Model structure and control of bone remodeling: A theoretical study
Peter Pivonka et al.
BONE (2008)
Intratumor heterogeneity of epidermal growth factor receptor mutations in lung cancer and its correlation to the response to gefitinib
Kazuya Taniguchi et al.
CANCER SCIENCE (2008)
Cancer cell metabolism: Warburg and beyond
Peggy P. Hsu et al.
CELL (2008)
Circulating mutant DNA to assess tumor dynamics
Frank Diehl et al.
NATURE MEDICINE (2008)
Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer
P. J. Roberts et al.
ONCOGENE (2007)
A stochastic model for the sizes of detectable metastases
Leonid Hanin et al.
JOURNAL OF THEORETICAL BIOLOGY (2006)
Systems biology and combination therapy in the quest for clinical efficacy
Jonathan B. Fitzgerald et al.
NATURE CHEMICAL BIOLOGY (2006)
Numerical integration of stochastic differential equations with nonglobally Lipschitz coefficients
GN Milstein et al.
SIAM JOURNAL ON NUMERICAL ANALYSIS (2005)
Modeling cancer detection: tumor size as a source of information on unobservable stages of carcinogenesis
R Bartoszynski et al.
MATHEMATICAL BIOSCIENCES (2001)
A mathematical model to study the effects of drug resistance and vasculature on the response of solid tumors to chemotherapy
TL Jackson et al.
MATHEMATICAL BIOSCIENCES (2000)
Share Paper
